Cargando…
Progression to end-stage renal disease is reduced with eculizumab in patients with atypical haemolytic uraemic syndrome
Autores principales: | Walle, J Vande, Johnson, S, Harvey, E, Kincaid, J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4472974/ http://dx.doi.org/10.1186/cc14409 |
Ejemplares similares
-
Early initiation of eculizumab treatment in patients with atypical haemolytic uraemic syndrome improves long-term outcomes: a pooled analysis of clinical trials
por: Walle, J Vande, et al.
Publicado: (2015) -
Eculizumab in secondary atypical haemolytic uraemic syndrome
por: Cavero, Teresa, et al.
Publicado: (2017) -
Eculizumab treatment of atypical haemolytic uraemic syndrome: results from the largest prospective clinical trial to date
por: weekers, LE, et al.
Publicado: (2014) -
Early treatment with eculizumab in atypical haemolytic uraemic syndrome
por: Garjau, Maria, et al.
Publicado: (2012) -
Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis
por: Socié, Gérard, et al.
Publicado: (2019)